Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.

• Tác giả: Jianhua Gong, Cuicui Li, Jun Liu, Xia Lu, Qingfang Miao, Jigang Yang, Xu Yang, Lingling Zheng, Ziang Zhou, Xianyu Zhu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 796.019 Psychological principles
• Thông tin xuất bản: Germany : European journal of nuclear medicine and molecular imaging , 2025
• Bộ sưu tập: NCBI
• ID: 720320

Tóm tắt

PURPOSE: CD30 serves as an ideal therapeutic target for lymphoma, but its variable expression and high relapse rate pose challenges in targeted therapy. This study aims to label the anti-CD30 monoclonal antibody with METHODS: CD30 binding kinetics of anti-CD30-IgG (IMB16) were measured by Biolayer interferometry (BLI). Western blotting screened lymphoma cell lines for CD30 expression. Flow cytometry and immunofluorescence validated the specific binding of IMB16. IMB16 was conjugated to p-SCN-Bn-NOTA(NOTA) and p-SCN-Bn-DOTA(DOTA) for radiolabeling with RESULTS: IMB16 had a strong binding affinity to CD30 according to the BLI. Western blotting revealed high CD30 expression in Karpas299 cells and negative expression in Raji cells. Flow cytometry and immunofluorescence confirmed specific binding of IMB16 to CD30 on cell surface. Radiochemical purity of [ CONCLUSIONS: Labelling IMB16 with